Clinical Trial

177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With High and Very High Risk Prostate Cancer

Study acronym: PSMA-ADJUVO
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Single-center, non-commercial phase 2 clinical trial to evaluate 177Lu-PSMA as a systemic adjuvant treatment in patients with high and very high risk prostate cancer after radical treatment using locoregional teleradiotherapy and hormone therapy
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-06-07.
Status change: Not Yet Recruiting → Recruiting 2025-02-05
Trial Details
NCT Number NCT06449781
Lead Sponsor Maria Sklodowska-Curie National Research Institute of Oncology
Conditions Prostate Cancer
Enrollment 200 participants
Start Date 2025-01-09
Primary Completion 2030-11 (estimated)
Study Completion 2030-11 (estimated)
Updated on ClinicalTrials.gov 2025-02-10